USPTO serial 88534482
CANCEROME
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- HENRY, NAKIA D
- Law office
- TMO LAW OFFICE 129 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with CANCEROME?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jason C. Cameron
Jason C. Cameron JCameron IP Law LLC13102 Plumwood DriveCypress, TX 77429United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Diagnostic preparations for clinical or medical laboratory use; Diagnostic preparations for scientific or research use; Diagnostic preparations for scientific or research use other than for medical use; Diagnostic preparations for scientific use; Diagnostic preparations other than for medical or veterinary purposes; Diagnostic preparations used in science; Diagnostic preparations, other than for medical or veterinary purposes; Diagnostic reagents and preparations, except for medical or veterinary use; Diagnostic reagents for clinical or medical laboratory use; Diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; Diagnostic reagents for scientific or research use; Diagnostic reagents for scientific use; Active chemical ingredients for use in the manufacture of anti-cancer drugs; Immunohistochemistry detection kits consisting of mouse secondary reagents, DAB chromogens, DAB buffers, peroxidase blocking reagent, and hematoxylin, for anatomic pathology purposes in the medical diagnostics industry; Laboratory chemicals, namely, an antibody reagent used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use | ACTIVE | Aug 4, 2023 |
| 005 | Diagnostic agents, preparations and substances for medical purposes; Diagnostic biomarker reagents for medical purposes; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, cancer; Diagnostic media for bacteriological cultures; Diagnostic preparations for medical and veterinary use; Diagnostic preparations for medical or veterinary purposes; Diagnostic preparations for medical purposes; Diagnostic preparations for veterinary purposes; Diagnostic radiopharmaceutical agent for use in PET imaging; Diagnostic radiopharmaceutical preparations; Diagnostic reagents and contrast media for medical use; Diagnostic reagents for medicinal use; Diagnostic test patch for application to the skin for determining allergic reactions; Diagnostic test patch for application to the skin for determining allergies; Therapeutic vaccines; Anti-cancer preparations; Biological preparations for the treatment of cancer; Biometallic compounds for consumption and/or injection for use in medical imaging and for diagnostic purposes; Contrasting agent for ultrasound diagnostic imaging; Medical diagnostic reagents; Medical diagnostic reagents and assays for testing body fluids for microorganisms; Medical diagnostic reagents and assays for testing of body fluids; Medical diagnostic reagents for the analysis of body fluids; Medical diagnostic test strips for use in the field of early detection of cancer; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Radio-isotope markers for therapeutic or diagnostic use; Radioactive pharmaceutical preparations for use in vivo diagnostic or therapeutic use; Radiopharmaceutical imaging and detection agents for diagnosing and monitoring cancer; Veterinary diagnostic reagents | ACTIVE | Aug 4, 2023 |
| 010 | Diagnostic apparatus for the detection of cancer; Diagnostic apparatus for the detection of periodontal disease; Diagnostic kits consisting primarily of probes, buffers and reagents for use in microbial testing; Diagnostic penlights for medical purposes; Audio oscillators for detecting toxins and pathogens in the body for medical diagnostic purposes; Cytometers for medical diagnostic use; Dynamometers for diagnostic muscle strength testing; Electromagnetic medical diagnostic imaging apparatus; Flow cytometers for medical diagnostic uses; Hematology analyzers for medical diagnostic uses; Medical diagnostic apparatus for analyzing and measuring electrolytes in the body; Medical diagnostic apparatus for detecting cancer; Medical diagnostic apparatus for testing DNA and RNA samples; Medical diagnostic instruments for the analysis of body fluids; Medical apparatus and instrument for diagnostic use, namely, apparatus for medical diagnostic testing in the fields of cancer or other tissue-based diagnostic testing, cytology and cell-based testing; Medical apparatus and instruments for diagnostic radiopharmaceutical use; Medical apparatus for detecting cancer; Medical device for detecting cancer; Medical device for treating cancer; Nuclear medicine diagnostic imaging apparatus; Organoleptic diagnostic testing apparatus for medical, dental or cosmetic use; Orthopedic devices for diagnostic and therapeutic use; Radiological apparatus for diagnostic and medical purposes, namely, magnetic resonance imager; Sample preparation device for medical diagnostic uses; Ultrasonic medical diagnostic apparatus; Ultrasound diagnostic apparatus; X-ray diagnostic apparatus | ACTIVE | Aug 4, 2023 |
| 042 | Diagnostic services in the field of machines that detect cancer; Automobile transmission diagnostic services; Computer diagnostic services; Consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics; Medical and scientific research in the field of cancer treatment and diagnosis; Medical research services in the field of cancer; Providing a website featuring information about investigational medical devices, diagnostics and drugs; Providing laboratory research services in the field of gene expression, namely, cancer biology; Providing medical testing services and information in the field of cancer research and disease classification; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Scientific research for medical purposes in the area of cancerous diseases | ACTIVE | Aug 4, 2023 |
| 044 | Medical diagnostic services for cancer detection | ACTIVE | Aug 4, 2023 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by INanoBio Inc
- Other trademarks owned by INanoBio Inc
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named CANCEROME
- Prosecution event MAB2 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 14, 2024 | MAB2 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Apr 14, 2024 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Dec 7, 2023 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Dec 7, 2023 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Sep 8, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 8, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 8, 2023 | CNRT | SU - NON-FINAL ACTION - WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 14, 2023 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Aug 11, 2023 | IUAF | USE AMENDMENT FILED | — |
| Aug 11, 2023 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Jan 24, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 23, 2023 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Jan 11, 2023 | EXT5 | SOU EXTENSION 5 FILED | — |
| Jan 11, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 13, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 11, 2022 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Aug 11, 2022 | EXT4 | SOU EXTENSION 4 FILED | — |
| Aug 11, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 6, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 4, 2022 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Jan 4, 2022 | EXT3 | SOU EXTENSION 3 FILED | — |
| Jan 4, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 25, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 24, 2021 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Sep 23, 2021 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Sep 15, 2021 | NREV | NOTICE OF REVIVAL - E-MAILED | — |
| Sep 15, 2021 | TPEX | SOU EXTENSION RECEIVED WITH TEAS PETITION | — |
| Sep 15, 2021 | PETG | PETITION TO REVIVE-GRANTED | — |
| Sep 15, 2021 | PROA | TEAS PETITION TO REVIVE RECEIVED | — |
| Sep 13, 2021 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Sep 13, 2021 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Aug 11, 2021 | EXT2 | SOU EXTENSION 2 FILED | — |
| Feb 18, 2021 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Feb 18, 2021 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Feb 18, 2021 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 18, 2021 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Feb 4, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 2, 2021 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Feb 2, 2021 | EXT1 | SOU EXTENSION 1 FILED | — |
| Feb 2, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 11, 2020 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jun 16, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 16, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 27, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 14, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 11, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 10, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 10, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 22, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 22, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 22, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 20, 2019 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Nov 12, 2019 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Oct 30, 2019 | ALIE | ASSIGNED TO LIE | — |
| Oct 21, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 21, 2019 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Oct 21, 2019 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Oct 21, 2019 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Oct 21, 2019 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Oct 14, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 2, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 29, 2019 | NWAP | NEW APPLICATION ENTERED | — |